Literature DB >> 32020248

Differential expression of the inflammasome complex genes in systemic lupus erythematosus.

Heidi Lacerda Alves da Cruz1, Catarina Addobbati Jordão Cavalcanti1,2, Jaqueline de Azêvedo Silva1, Camilla Albertina Dantas de Lima1, Thiago Sotero Fragoso3, Alexandre Domingues Barbosa4, Andréa Tavares Dantas4, Henrique de Ataíde Mariz4, Angela Luzia Branco Pinto Duarte4, Alessandra Pontillo5, Sergio Crovella1,2, Paula Sandrin-Garcia6,7.   

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder involving heterogeneous clinical manifestations and numerous susceptibility genes. Several findings evidence the critical role of inflammasomes in the predisposition to autoimmune diseases and in SLE. We investigated whether inflammasome polymorphins could affect susceptibility to develop and/or severity SLE. Moreover, differences in inflammasome activation in peripheral blood were also evaluated in SLE patients and controls. The distribution of 13 SNPs in eight inflammasome genes was evaluated. To assess inflammasome priming in peripheral blood monocytes of SLE and controls, differential expression of selected inflammasome genes and IL-1ß production was analyzed in resting condition as well as after LPS and ATP stimulation. Results showed that the gain-of-function variant rs10754558 (NLRP3) was significantly more frequent in SLE patients with nephritis, reinforcing the concept of a key role of NLRP3 inflammasome not only in SLE but also especially in kidney disease. SLE monocytes in resting condition showed a higher level of IL-1ß expression and produced higher levels of IL-1ß when stimulated with LPS+ATP comparing to controls. The stimulation induced a significant expression of NLRP1, AIM2, CASP1, and IL1B genes, suggesting that the NLRP1 inflammasome is responsible for the IL-1ß production observed in monocytes. These data emphasized once more the important contribution of inflammasome in SLE-associated inflammation.

Entities:  

Keywords:  Gene expression; Inflammasome; Nephritis; Polymorphisms; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2020        PMID: 32020248     DOI: 10.1007/s00251-020-01158-6

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  40 in total

Review 1.  Regulation of inflammasome activation.

Authors:  Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

2.  Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Seth G Thacker; Celine C Berthier; Clemens D Cohen; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2011-11-04       Impact factor: 5.422

Review 3.  Genetics of susceptibility and severity in systemic lupus erythematosus.

Authors:  Jennifer A Croker; Robert P Kimberly
Journal:  Curr Opin Rheumatol       Date:  2005-09       Impact factor: 5.006

4.  Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation.

Authors:  Pei-Yi Tsai; Shuk-Man Ka; Jia-Ming Chang; Hsiang-Cheng Chen; Hao-Ai Shui; Chen-Yun Li; Kuo-Feng Hua; Wen-Liang Chang; Jiann-Jyh Huang; Sung-Sen Yang; Ann Chen
Journal:  Free Radic Biol Med       Date:  2011-05-23       Impact factor: 7.376

5.  Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease.

Authors:  R L Roberts; R K G Topless; A J Phipps-Green; R B Gearry; M L Barclay; T R Merriman
Journal:  Genes Immun       Date:  2010-02-25       Impact factor: 2.676

6.  Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil.

Authors:  A Pontillo; L Brandao; R Guimaraes; L Segat; J Araujo; S Crovella
Journal:  Autoimmunity       Date:  2010-04-07       Impact factor: 2.815

7.  The missense variation Q705K in CIAS1/NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease.

Authors:  Alessandra Pontillo; Anna Vendramin; Eulalia Catamo; Annalisa Fabris; Sergio Crovella
Journal:  Am J Gastroenterol       Date:  2011-01-18       Impact factor: 10.864

8.  Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases.

Authors:  J F Camargo; P A Correa; J Castiblanco; J-M Anaya
Journal:  Genes Immun       Date:  2004-12       Impact factor: 2.676

9.  Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages.

Authors:  J Michelle Kahlenberg; Carmelo Carmona-Rivera; Carolyne K Smith; Mariana J Kaplan
Journal:  J Immunol       Date:  2012-12-24       Impact factor: 5.422

10.  Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation.

Authors:  Shuk-Man Ka; Jung-Chen Lin; Tsai-Jung Lin; Feng-Cheng Liu; Louis Kuoping Chao; Chen-Lung Ho; Li-Tzu Yeh; Huey-Kang Sytwu; Kuo-Feng Hua; Ann Chen
Journal:  Arthritis Res Ther       Date:  2015-11-19       Impact factor: 5.156

View more
  7 in total

Review 1.  Insights into inflammasome regulation: cellular, molecular, and pathogenic control of inflammasome activation.

Authors:  Naveen Challagundla; Bhaskar Saha; Reena Agrawal-Rajput
Journal:  Immunol Res       Date:  2022-05-24       Impact factor: 4.505

2.  Variability of the rs333 in Polish patients with lupus erythematosus.

Authors:  Dominika Mlicka; Anna Duleba; Rafał Czajkowski; Mariusz Gawrych; Anna Woźniacka; Ewa Robak; Marta Gorzkiewicz; Szymon Kozłowski; Tomasz Grzybowski; Katarzyna Skonieczna
Journal:  Postepy Dermatol Alergol       Date:  2021-03-10       Impact factor: 1.837

Review 3.  Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus.

Authors:  Yaling Liu; Xinyu Tao; Jinhui Tao
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

4.  Is there an Inflammation Role for MYD88 in Rheumatoid Arthritis?

Authors:  Isaura Isabelle Fonseca Gomes da Silva; Camilla Albertina Dantas Lima; José Eduardo Adelino Silva; Eliezer Rushansky; Maria Helena Queiroz Araujo Mariano; Patrícia Rolim; Renê Donizeti Ribeiro Oliveira; Paulo Louzada-Júnior; Fabricio Oliveira Souto; Sergio Crovella; Jaqueline de Azevêdo Silva; Paula Sandrin-Garcia
Journal:  Inflammation       Date:  2021-01-06       Impact factor: 4.092

Review 5.  Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective.

Authors:  Santosh V Suryavanshi; Igor Kovalchuk; Olga Kovalchuk
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

Review 6.  The Role of NLRP3 Inflammasome in Lupus Nephritis.

Authors:  Camila Barbosa Oliveira; Camilla Albertina Dantas Lima; Gisele Vajgel; Paula Sandrin-Garcia
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

Review 7.  The Role of Inflammasomes in Glomerulonephritis.

Authors:  Paula Anton-Pampols; Clara Diaz-Requena; Laura Martinez-Valenzuela; Francisco Gomez-Preciado; Xavier Fulladosa; Anna Vidal-Alabro; Joan Torras; Núria Lloberas; Juliana Draibe
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.